CETP

CETP製品

All (4)
CETP阻害剤 (4)
新製品

製品コード	製品名称	製品説明	文献中Selleckの製品使用例	お客様のフィードバック
S2748	Anacetrapib (MK-0859)	Anacetrapib (MK0859) is a potent, selective, reversible rhCETP and mutant CETP(C13S) inhibitor with IC50 of 7.9 nM and 11.8 nM, increases HDL-C and decreases LDL-C, does not increase aldosterone or blood pressure. Phase 3.	Circulation, 2021, 143(9):921-934 J Phys Chem B, 2016, 120(33):8254-63 Atherosclerosis, 2014, 235(2):449-62
S2772	Dalcetrapib (JTT-705)	Dalcetrapib (JTT-705) is a rhCETP inhibitor with IC50 of 0.2 μM that increases the plasma HDL cholesterol. Phase 3.	Atherosclerosis, 2014, 235(2):449-62
S2792	Torcetrapib	Torcetrapib (CP-529414) is a CETP inhibitor with IC50 of 37 nM, elevates HDL-C and reduces nonHDL-C in plasma. Phase 3.
S2925	Evacetrapib (LY2484595)	Evacetrapib (LY2484595) is a potent and selective inhibitor of CETP with IC50 of 5.5 nM, elevates HDL cholesterol without increases in aldosterone or blood pressure. Phase 3.
S2748	Anacetrapib (MK-0859)	Anacetrapib (MK0859) is a potent, selective, reversible rhCETP and mutant CETP(C13S) inhibitor with IC50 of 7.9 nM and 11.8 nM, increases HDL-C and decreases LDL-C, does not increase aldosterone or blood pressure. Phase 3.	Circulation, 2021, 143(9):921-934 J Phys Chem B, 2016, 120(33):8254-63 Atherosclerosis, 2014, 235(2):449-62
S2772	Dalcetrapib (JTT-705)	Dalcetrapib (JTT-705) is a rhCETP inhibitor with IC50 of 0.2 μM that increases the plasma HDL cholesterol. Phase 3.	Atherosclerosis, 2014, 235(2):449-62
S2792	Torcetrapib	Torcetrapib (CP-529414) is a CETP inhibitor with IC50 of 37 nM, elevates HDL-C and reduces nonHDL-C in plasma. Phase 3.
S2925	Evacetrapib (LY2484595)	Evacetrapib (LY2484595) is a potent and selective inhibitor of CETP with IC50 of 5.5 nM, elevates HDL cholesterol without increases in aldosterone or blood pressure. Phase 3.

CETP阻害剤の選択性比較

CETPシグナル伝達経路

CETPシグナル伝達経路

Tags: CETP inhibitor|CETP agonist|CETP activator|CETP inducer|CETP antagonist|CETP signaling pathway|CETP assay kit